Skip to main content

Table 2 Clinical remission of iMN patients during the follow-up period

From: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients

Time

Clinical remission

Low-level group(n = 52)

High-level group(n = 42)

P value

6 months

CR, n (%)

5 (9.6%)

0 (0%)

0.047

PR, n (%)

22 (42.3%)

8 (19%)

0.140

TR, n (%)

27 (51.9%)

8 (19%)

0.001

NR, n (%)

25 (48.1%)

34 (81%)

 0.001

12 months

CR, n (%)

22 (42.3%)

2 (4.7%)

< 0.001

PR, n (%)

21 (40.4%)

14 (33.3%)

0.313

TR, n (%)

43 (82.7%)

16 (38%)

< 0.001

NR, n (%)

9 (17.3%)

26 (62%)

< 0.001

18 months

CR, n (%)

27 (51.9%)

6 (14.3%)

< 0.001

PR, n (%)

19 (36.6%)

12 (28.6%)

0.276

TR, n (%)

46 (88.5%)

18 (42.9%)

< 0.001

NR, n (%)

6 (11.5%)

24 (57.1%)

< 0.001

24 months

CR, n (%)

27 (51.9%)

9 (21.45%)

0.002

PR, n (%)

19 (36.6%)

9 (21.45%)

0.085

TR, n (%)

46 (88.5%)

18 (42.9%)

< 0.001

NR, n (%)

6 (11.5%)

24 (57.1%)

< 0.001

  1. Bold indicate p value < 0.05
  2. Legend: iMN idiopathic membranous nephropathy, low-level group anti-PLA2R antibody titer ≤ 150 RU/ml, high-level group anti-PLA2R antibody titer > 150 RU/ml, CR complete remission, PR partial remission, TR total remission, NR no response